Doctors Have a Only a Few Weeks Left to Review Financial Data

Share this content:
Doctors Have a Only a Few Weeks Left to Review Financial Data
Doctors Have a Only a Few Weeks Left to Review Financial Data

WEDNESDAY, April 27, 2016 (HealthDay News) -- Under the Physician Payments Sunshine Act, physicians have only a few weeks left to review and report disputes relating to their financial ties to drug and medical device manufacturers, according to the American Medical Association.

The Centers for Medicare & Medicaid Services (CMS) announced the start of a 45-day review and dispute period, which will end on May 15. Disputes filed during this time will be flagged in the Open Payment data prior to publication of the 2015 data. Disputes submitted after the deadline will not be flagged for the initial release.

The Open Payments program has been established to increase transparency and accountability within health care, but has seen issues with inaccurate data. In order to dispute any inaccurate data reported, physicians must complete the CMS e-verification process, register with the Open Payments system, and review data and dispute any inaccuracies. Any disputes can be followed through the portal from initiation to resolution.

"Physicians have three weeks left to review and dispute reports regarding their financial interactions with manufacturers of drugs and medical devices reported under the Physician Payments Sunshine Act, also known as the Open Payments program," according to the article.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »